Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

Sunday, November 29, 2009

Bad drug reactions in people with systemic body odor

Systemic body odor/halitosis : Do you have bad reactions to drugs/medicines ?

People with systemic body odor and/or halitosis often mention they have bad reactions to drugs. This isn't surprising, since drugs and odorous compounds are probably often dealt with by the phase1/phase2 biotransformation enzyme group of enzymes, of which FMO3 is one. In general, we have 2 'layers' of these enzymes, phase1 and phase2 (in truth there are many exceptions to the 'rules'). FMO3 is one of the phase1 enzymes, along with the CYP450 family of enzymes, which is regarded as the 'main player' in Phase1 (perhaps because greater understanding of FMO3 is needed). These enzymes are often involved in oxidation reactions (such as FMO3 oxidizing trimethylamine to trimethylamine-n-oxide).

FMO3 is very commonly involved in many oxidation reactions (probably thousands of substrates). Often, a substrate can take an alternative slower route if for some reason the preferred enzyme is saturated (though not trimethylamine, apparently).

In this paper, the researchers looked at the 'clearance' from the blood (detoxification) of the drug Voriconazole. They say that most of the detoxification of voriconazole in humans is done by CYP3A4, CYP2C19, and flavin-containing monooxygenase 3 (FMO3). Apparently in children the clearance rate is faster because they don't use CYP3A4 so much.

body odorAlthough researchers learn more about these enzymes, each paper must be taken with some trepidation, in that often on the journey to agreement about facts, they contradict each other. However as time goes by, a picture emerges.

Whilst having no FMO3 enzyme does not seem to result in death or visual illness, and those with reduced FMO3 function are expected to live a normal lifespan, the enzyme seems to be involved in thousands of substrate oxidation reactions. So it is likely that most FMO3 research is more likely going to be a consequence to bad reactions to drugs (or uselessness of drugs that these enzymes activate, as well as detoxicate) rather than for trimethylaminuria, which the medical community probably has no interest in. Not unless we can promote or petition for research ourselves.
In Vitro Hepatic Metabolism Explains Higher Clearance of Voriconazole in Children versus Adults: Role of CYP2C19 and FMO3.
Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK, Thakker DR.
1 The University of North Carolina at Chapel Hill;

Voriconazole is a broad spectrum antifungal agent for treating life threatening fungal infections. Its clearance is approximately three-fold higher in children compared to adults. Voriconazole is cleared predominantly via hepatic metabolism in adults, mainly by CYP3A4, CYP2C19, and flavin-containing monooxygenase 3 (FMO3). In vitro metabolism of voriconazole by liver microsomes prepared from pediatric and adult tissues (n=6/group) mirrored the in vivo clearance differences in children versus adults, and showed that the oxidative metabolism was significantly faster in children compared to adults as indicated by the in vitro half-life (T (1/2)) of 33.8 +/- 15.3 versus 72.6 +/- 23.7 min, respectively. The K(m) for voriconazole metabolism to N-oxide, the major metabolite formed in humans, by liver microsomes from children and adults was similar (11.0 +/- 5.2 muM versus 9.3 +/- 3.6 muM, respectively). In contrast, apparent V(max) was approximately 3-fold higher in children compared to adults (120.5 +/- 99.9 versus 40.0 +/- 13.9 pmol/min/mg). The calculated in vivo clearance from in vitro data was found to be approximately 80% of the observed plasma clearance values in both populations. Metabolism studies in which CYP3A4, CYP2C19, or FMO was selectively inhibited provided evidence that contribution of CYP2C19 and FMO toward voriconazole N-oxidation was much greater in children than in adults, whereas CYP3A4 played a larger role in adults. While expression of CYP2C19 and FMO3 is not significantly different in children versus adults, these enzymes appear to contribute to higher metabolic clearance of voriconazole in children versus adults.


Post a Comment